Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT04179110
Title Study of Pembrolizumab and Ramucirumab in Pts With Progressive TCC After Treatment With an Immune Checkpoint Inhibitor
Recruitment Withdrawn
Gender both
Phase Phase II
Variant Requirements No
Sponsors Yale University

urethra transitional cell carcinoma

bladder urothelial carcinoma

renal pelvis transitional cell carcinoma


Pembrolizumab + Ramucirumab

Age Groups: adult | senior
Covered Countries USA

No variant requirements are available.